Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:HOOK NASDAQ:PWUP NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.67-42.6%$8.63$1.52▼$75.00$5.41M0.791,500 shs4.14 million shsHOOKHOOKIPA Pharma$0.88+4.8%$1.20$0.72▼$5.66$10.24M0.93188,481 shs147,712 shsPWUPPowerUp Acquisition$0.35-3.0%$0.36$8.05▼$15.80$2.75M0.053,464 shs624,234 shsSNSESensei Biotherapeutics$7.50+4.0%$7.78$5.00▼$17.40$9.09M0.2626,550 shs16,577 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie-42.61%-72.31%-79.25%-85.02%-92.34%HOOKHOOKIPA Pharma+4.82%-0.51%-27.23%-32.27%-82.07%PWUPPowerUp Acquisition0.00%-17.36%+23.71%-0.79%-96.88%SNSESensei Biotherapeutics+4.04%-27.32%-16.66%+4.18%-40.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie0.6084 of 5 stars0.02.00.00.03.60.00.6HOOKHOOKIPA Pharma2.8401 of 5 stars3.25.00.00.01.12.50.6PWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics4.7691 of 5 stars3.75.00.04.83.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 4.00Strong BuyN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50411.07% UpsidePWUPPowerUp Acquisition 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$55.00633.24% UpsideCurrent Analyst Ratings BreakdownLatest PWUP, HOOK, BIVI, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$100.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$25.35 per shareN/AHOOKHOOKIPA Pharma$43.95M0.24N/AN/A$4.25 per share0.21PWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$21.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$79.10N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/14/2025 (Estimated)PWUPPowerUp AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$30.16M-$21.31N/AN/AN/AN/A-72.13%-61.35%N/ALatest PWUP, HOOK, BIVI, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HOOKHOOKIPA Pharma-$0.64N/AN/AN/AN/AN/A8/5/2025Q2 2025SNSESensei Biotherapeutics-$6.20-$3.91+$2.29-$3.91N/AN/A5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/12/2025Q3 2025BIVIBioVie-$3.20-$1.50+$1.70-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.319.31HOOKHOOKIPA PharmaN/A3.613.61PWUPPowerUp AcquisitionN/AN/AN/ASNSESensei BiotherapeuticsN/A7.646.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%HOOKHOOKIPA Pharma63.88%PWUPPowerUp Acquisition19.17%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%HOOKHOOKIPA Pharma3.30%PWUPPowerUp Acquisition48.00%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie101.86 million1.82 millionNo DataHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionablePWUPPowerUp AcquisitionN/A7.77 million4.04 millionNot OptionableSNSESensei Biotherapeutics401.26 million968,000Not OptionablePWUP, HOOK, BIVI, and SNSE HeadlinesRecent News About These CompaniesQ3 EPS Estimate for Sensei Biotherapeutics Lifted by AnalystAugust 8 at 2:38 AM | americanbankingnews.comSensei (SNSE) Q2 Loss Narrows 31%August 6 at 2:01 AM | fool.comSensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 5, 2025 | globenewswire.comThese 3 health tech stocks spiked 37% in a day; Time to buy?August 4, 2025 | finbold.comFSensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025July 30, 2025 | globenewswire.comSensei Biotherapeutics to execute 1-for-20 reverse stock splitJune 13, 2025 | kalkinemedia.comKSensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitJune 13, 2025 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 28, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 28, 2025 | baystreet.caSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 28, 2025 | markets.businessinsider.comSensei Biotherapeutics price target raised to $4 from $3.50 at OppenheimerMarch 28, 2025 | markets.businessinsider.comSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressMarch 28, 2025 | globenewswire.comSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsMarch 27, 2025 | globenewswire.comWhat Makes Sensei Biotherapeutics (SNSE) a New Buy StockFebruary 6, 2025 | zacks.comSensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | markets.businessinsider.comSensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comSensei Biotherapeutics Inc (SNSE) Stock: Unveiling Its Hidden StrengthsJanuary 18, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimePWUP, HOOK, BIVI, and SNSE Company DescriptionsBioVie NASDAQ:BIVI$1.67 -1.24 (-42.61%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.61 -0.06 (-3.83%) As of 08/8/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.HOOKIPA Pharma NASDAQ:HOOK$0.88 +0.04 (+4.78%) As of 08/8/2025 03:47 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.PowerUp Acquisition NASDAQ:PWUP$0.35 -0.01 (-2.99%) As of 08/5/2025PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Sensei Biotherapeutics NASDAQ:SNSE$7.50 +0.29 (+4.04%) Closing price 08/8/2025 03:58 PM EasternExtended Trading$8.32 +0.82 (+10.99%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
